{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T06:10:02Z","timestamp":1735539002184,"version":"3.32.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,29]]},"DOI":"10.7759\/cureus.76593","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T05:29:01Z","timestamp":1735536541000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of Melatonin Treatment in Patients With Central Serous Chorioretinopathy"],"prefix":"10.7759","author":[{"given":"Fuat","family":"Yavrum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nedime","family":"Sahinoglu-Keskek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002","volume":"115","author":"Kitzmann AS","year":"2008","unstructured":"Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008, 115:169-73. 10.1016\/j.ophtha.2007.02.032","journal-title":"Ophthalmology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130681007","article-title":"The long-term outcome of central serous chorioretinopathy","volume":"114","author":"Yap EY","year":"1996","unstructured":"Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996, 114:689-92. 10.1001\/archopht.1996.01100130681007","journal-title":"Arch Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0847","article-title":"The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders","volume":"4","author":"Pandi-Perumal SR","year":"2008","unstructured":"Pandi-Perumal SR, Trakht I, Spence DW, Srinivasan V, Dagan Y, Cardinali DP. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol. 2008, 4:436-47. 10.1038\/ncpneuro0847","journal-title":"Nat Clin Pract Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1051\/rnd:19990310","article-title":"Melatonin mediates seasonal adjustments in immune function","volume":"39","author":"Nelson RJ","year":"1999","unstructured":"Nelson RJ, Drazen DL. Melatonin mediates seasonal adjustments in immune function. Reprod Nutr Dev. 1999, 39:383-98. 10.1051\/rnd:19990310","journal-title":"Reprod Nutr Dev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/157015910792246155","article-title":"Antiinflammatory activity of melatonin in central nervous system","volume":"8","author":"Esposito E","year":"2010","unstructured":"Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol. 2010, 8:228-42. 10.2174\/157015910792246155","journal-title":"Curr Neuropharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-079X.2005.00304.x","article-title":"Protective effects of melatonin in experimental free radical-related ocular diseases","volume":"40","author":"Siu AW","year":"2006","unstructured":"Siu AW, Maldonado M, Sanchez-Hidalgo M, Tan DX, Reiter RJ. Protective effects of melatonin in experimental free radical-related ocular diseases. J Pineal Res. 2006, 40:101-9. 10.1111\/j.1600-079X.2005.00304.x","journal-title":"J Pineal Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-079X.2010.00762.x","article-title":"Melatonin: a novel neuroprotectant for the treatment of glaucoma","volume":"48","author":"Belforte NA","year":"2010","unstructured":"Belforte NA, Moreno MC, de Zaval\u00eda N, Sande PH, Chianelli MS, Keller Sarmiento MI, Rosenstein RE. Melatonin: a novel neuroprotectant for the treatment of glaucoma. J Pineal Res. 2010, 48:353-64. 10.1111\/j.1600-079X.2010.00762.x","journal-title":"J Pineal Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.104","article-title":"Therapeutic benefit of melatonin in refractory central serous chorioretinopathy","volume":"29","author":"Gramajo AL","year":"2015","unstructured":"Gramajo AL, Marquez GE, Torres VE, Ju\u00e1rez CP, Rosenstein RE, Luna JD. Therapeutic benefit of melatonin in refractory central serous chorioretinopathy. Eye (Lond). 2015, 29:1036-45. 10.1038\/eye.2015.104","journal-title":"Eye (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000267333","article-title":"Treatment of experimental acute corneal inflammation with inhibitors of the oxidative metabolism","volume":"25","author":"Alio JL","year":"1993","unstructured":"Alio JL, Ayala MJ, Mulet E, Artola A, Bellot JL, Ruiz-Moreno JM. Treatment of experimental acute corneal inflammation with inhibitors of the oxidative metabolism. Ophthalmic Res. 1993, 25:331-6. 10.1159\/000267333","journal-title":"Ophthalmic Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.63.10.674","article-title":"Argon laser photocoagulation in the treatment of central serous retinopathy","volume":"63","author":"Leaver P","year":"1979","unstructured":"Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1979, 63:674-7. 10.1136\/bjo.63.10.674","journal-title":"Br J Ophthalmol"},{"key":"ref11","article-title":"Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization-first report from the sultanate of Oman","volume":"23","author":"Wali UK","year":"2008","unstructured":"Wali UK, Al-Kharousi N, Hamood H. Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization-first report from the sultanate of Oman. Oman Med J. 2008, 23:282-6.","journal-title":"Oman Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000314709","article-title":"Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy","volume":"225","author":"Inoue M","year":"2011","unstructured":"Inoue M, Kadonosono K, Watanabe Y, Kobayashi S, Yamane S, Arakawa A. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. Ophthalmologica. 2011, 225:37-40. 10.1159\/000314709","journal-title":"Ophthalmologica"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0568-y","article-title":"Oral medications for central serous chorioretinopathy: a literature review","volume":"34","author":"Fusi-Rubiano W","year":"2020","unstructured":"Fusi-Rubiano W, Saedon H, Patel V, Yang YC. Oral medications for central serous chorioretinopathy: a literature review. Eye (Lond). 2020, 34:809-24. 10.1038\/s41433-019-0568-y","journal-title":"Eye (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00503-7","article-title":"Image calibration in choroidal vascularity index measurement","volume":"9","author":"Shariati MM","year":"2023","unstructured":"Shariati MM, Shoeibi N. Image calibration in choroidal vascularity index measurement. Int J Retina Vitreous. 2023, 9:66. 10.1186\/s40942-023-00503-7","journal-title":"Int J Retina Vitreous"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002585","article-title":"Use of choroidal vascularity index for choroidal structural evaluation in central serous chorioretinopathy with choroidal neovascularization","volume":"40","author":"Kim RY","year":"2020","unstructured":"Kim RY, Chung DH, Kim M, Park YH. Use of choroidal vascularity index for choroidal structural evaluation in central serous chorioretinopathy with choroidal neovascularization. Retina. 2020, 40:1395-402. 10.1097\/IAE.0000000000002585","journal-title":"Retina"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001040","article-title":"Choroidal vascularity index in central serous chorioretinopathy","volume":"36","author":"Agrawal R","year":"2016","unstructured":"Agrawal R, Chhablani J, Tan KA, Shah S, Sarvaiya C, Banker A. Choroidal vascularity index in central serous chorioretinopathy. Retina. 2016, 36:1646-51. 10.1097\/IAE.0000000000001040","journal-title":"Retina"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2515841420950846","article-title":"Biomarkers for central serous chorioretinopathy","volume":"12","author":"Nkrumah G","year":"2020","unstructured":"Nkrumah G, Paez-Escamilla M, Singh SR, Rasheed MA, Maltsev D, Guduru A, Chhablani J. Biomarkers for central serous chorioretinopathy. Ther Adv Ophthalmol. 2020, 12:10.1177\/2515841420950846","journal-title":"Ther Adv Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000529474","article-title":"Choroidal vascularity index versus choroidal thickness as biomarkers of acute central serous chorioretinopathy","volume":"66","author":"Ruiz-Moreno JM","year":"2023","unstructured":"Ruiz-Moreno JM, Guti\u00e9rrez-Bonet R, Chandra A, Vupparaboina KK, Chhablani J, Ruiz-Medrano J. Choroidal vascularity index versus choroidal thickness as biomarkers of acute central serous chorioretinopathy. Ophthalmic Res. 2023, 66:627-35. 10.1159\/000529474","journal-title":"Ophthalmic Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2012.08.009","article-title":"Melatonin: an underappreciated player in retinal physiology and pathophysiology","volume":"103","author":"Tosini G","year":"2012","unstructured":"Tosini G, Baba K, Hwang CK, Iuvone PM. Melatonin: an underappreciated player in retinal physiology and pathophysiology. Exp Eye Res. 2012, 103:82-9. 10.1016\/j.exer.2012.08.009","journal-title":"Exp Eye Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12008","article-title":"Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats","volume":"54","author":"Salido EM","year":"2013","unstructured":"Salido EM, Bordone M, De Laurentiis A, Chianelli M, Keller Sarmiento MI, Dorfman D, Rosenstein RE. Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats. J Pineal Res. 2013, 54:179-89. 10.1111\/jpi.12008","journal-title":"J Pineal Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S471525","article-title":"The role and therapeutic potential of melatonin in degenerative fundus diseases: diabetes retinopathy and age-related macular degeneration","volume":"18","author":"Ma C","year":"2024","unstructured":"Ma C, Li H, Lu S, Li X. The role and therapeutic potential of melatonin in degenerative fundus diseases: diabetes retinopathy and age-related macular degeneration. Drug Des Devel Ther. 2024, 18:2329-46. 10.2147\/DDDT.S471525","journal-title":"Drug Des Devel Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01975-9","article-title":"Endocrine abnormalities in patients with central serous chorioretinopathy","volume":"110","author":"Haimovici R","year":"2003","unstructured":"Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003, 110:698-703. 10.1016\/S0161-6420(02)01975-9","journal-title":"Ophthalmology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0764","article-title":"Involvement of Bax protein in the prevention of glucocorticoid-induced thymocytes apoptosis by melatonin","volume":"145","author":"Hoijman E","year":"2004","unstructured":"Hoijman E, Rocha Viegas L, Keller Sarmiento MI, Rosenstein RE, Pecci A. Involvement of Bax protein in the prevention of glucocorticoid-induced thymocytes apoptosis by melatonin. Endocrinology. 2004, 145:418-25. 10.1210\/en.2003-0764","journal-title":"Endocrinology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000444058","article-title":"Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis","volume":"56","author":"Kapoor KG","year":"2016","unstructured":"Kapoor KG, Wagner AL. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis. Ophthalmic Res. 2016, 56:17-22. 10.1159\/000444058","journal-title":"Ophthalmic Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/327240-effect-of-melatonin-treatment-in-patients-with-central-serous-chorioretinopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T05:29:03Z","timestamp":1735536543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/327240-effect-of-melatonin-treatment-in-patients-with-central-serous-chorioretinopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.76593","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}